LogicFlo AI secures $2.7M seed funding to revolutionize life sciences workflows
Boston startup LogicFlo AI raises $2.7M to deploy AI agents for pharma and biotech teams, slashing high-stakes work timelines from weeks to hours while ensuring compliance.
Boston, June 30, 2025 — LogicFlo AI, a Boston-based startup, has announced a $2.7 million seed funding round led by Lightspeed to scale its AI agent platform for the pharmaceutical, biotech, and medtech industries. The funding will support product expansion, team growth, and deeper deployments with global life sciences organizations, including a Fortune 500 customer.
Founders Arun Ramakrishnan and Udith Vaidyanathan (CREDIT: Pradeep Kumar S).
A New Paradigm for Regulated Industries
Founded by Udith Vaidyanathan and Arun Ramakrishnan, LogicFlo offers a human-centric approach to AI in life sciences. Unlike traditional automation, LogicFlo's intelligent agents are designed to execute high-stakes, high-compliance tasks under human guidance, turning specialists into "CEOs of their own workflows."
"We are building automation for people," said Udith Vaidyanathan, LogicFlo's co-founder and CEO. "Our goal is to let experts focus on advancing medical science, not busywork."
Vaidyanathan, a former Abbott executive, and Ramakrishnan, who led deep learning efforts at Intuitive Surgical, bring deep domain expertise to the table. "Our agents are intelligent, composable, and production-ready," added Arun Ramakrishnan, co-founder and CTO. "They understand the nuance of scientific work."
From Systems of Record to Systems of Engagement
LogicFlo shifts the focus from passive data storage to active engagement. Its platform allows users to interact directly with AI agents that can take instruction, act, and deliver results. This marks a paradigm shift in how knowledge work is conducted in life sciences.
Dramatic Impact on Workflows
Deployed across medical affairs, regulatory, commercial, and quality teams, LogicFlo's agents have already demonstrated significant efficiency gains:
- Medical writing outputs reduced from weeks to minutes (up to 2000x faster).
- Medical information request responses cut from 1-2 weeks to 1-2 days.
Built for Compliance and Scalability
LogicFlo's agents operate within fully auditable, human-in-the-loop systems. They are SOP-aware, organization-adapted, and trained to follow company-specific templates and workflows. Agents collaborate as teams, breaking down tasks and escalating to humans only when necessary.
"We are at a once-in-a-generation inflection point," said Vaidyanathan. "AI agents can now unlock meaningful productivity in regulated work."
Investor Confidence
Rohil Bagga, VP Investments at Lightspeed, commented: "LogicFlo's platform empowers life sciences teams to build agentic workflows, dramatically boosting productivity. We're excited to support their vision."
Future Plans
With the new funding, LogicFlo will expand its agent libraries, deepen integrations with systems like Veeva and IQVIA, and grow its team to meet rising demand.
Media images can be found here.
About LogicFlo AI
LogicFlo AI is an AI agent platform purpose-built for life sciences, enabling expert teams to execute high-stakes work faster and more accurately. Learn more at https://logicflo.ai/ or follow on LinkedIn.
About Lightspeed
Lightspeed is a global venture capital firm backing disruptive innovations in Enterprise, Consumer, Health, and Fintech. Visit www.lsip.com for more.
Related News
UiPath pivots to AI agent services with Taiwan manufacturing driving growth
UiPath, a top RPA software developer, is shifting its strategy to focus on AI agent platform services. Richard Chen, regional VP for Asia-Pacific and Japan, noted Taiwan's manufacturing sector has become its leading revenue source in the region.
LogicFlo AI Secures 2.7M Seed Funding for Life Sciences AI Agents
LogicFlo AI, a Boston-based AI platform for life sciences, raised $2.7 million in seed funding led by Lightspeed Ventures to enhance AI-driven workflows in the sector.